cetuximab
释义
[医]西妥昔单抗；
权威例句
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck — NEJM
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immun...
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
1. But there are few studies on Cetuximab for treating Breast Cancer.
目前关于西妥昔单抗治疗乳腺癌的研究较少。
youdao
2. A total of 572 weeks (median, 8 weeks) of cetuximab treatment were completed.
共完成了572周的西妥昔单抗治疗，中位周期数为8周。
youdao
3. The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
本文综述了西妥昔单抗的药理作用及临床评价。
youdao
4. The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
youdao
5. Because ERBB2 isn't affected by cetuximab, this is an easy way for cancers to become resistant to the drug.
由于ERBB2不受西妥昔单抗的影响，这是一种使癌症对药物产生耐药性的简单方法。
youdao
6. But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.
但这些称为EGFR抑制因子如西妥昔单抗的药物对结肠癌的治疗还不是很有效。
youdao
7. The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
youdao
8. EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients.
欧洲药品局emea已经限制西妥昔单抗和帕尼单抗在这些患者使用。
youdao
9. The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more.
最新的研究看出如果加用西妥昔单抗(又名爱比妥)可以明显增加这种手术切除的优势。
youdao
10. Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.
治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
youdao
11. Objective: to determine the therapeutic effect and toxicity of cetuximab and chemotherapy agents in metastatic colorectal cancer.
目的：探讨西妥昔单抗联合化疗治疗转移性结直肠癌的疗效和不良反应。
youdao
12. Objective As EGFR inhibitor, Cetuximab has been widely used in several solid tumors, and has perfect therapeutic effect and security.
目的作为EGFR抑制剂，西妥昔单抗在多种实体瘤中应用日益广泛，显示出良好的疗效和安全性。
youdao
13. Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
youdao
14. The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
youdao
15. Proteomics and microarrays were used to monitor the molecular response to cetuximab and to identify profiles and biomarkers to predict treatment efficacy.
蛋白组学和微数列用来检测西妥昔单抗的分子有效性并且明确生物标记物对疗效的预测方面的作用。
youdao
16. For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.
例如，委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。
youdao
17. Conclusion Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
结论：我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
youdao
18. This paper aims to observe the short term efficiency and safety of Cetuximab combined with radiotherapy of head and neck squamous Cell carcinoma in Chinese patients.
本文旨在观察西妥昔单抗联合放疗对中国局部晚期头颈部鳞癌患者的近期疗效和安全性。
youdao
19. Conclusion: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.
结论：这些结果证实了：KRAS突变对于转移性CRC患者使用西妥昔单抗治疗时对西妥昔单抗耐药情况和生存期具有很高的预测价值。
youdao
20. Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
方法：我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
youdao
21. Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
方法：我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
youdao
cetuximab
